文献速递免疫规划慢病防控与筛查

2009年甲型H1N1流感大流行后挪威儿童和年轻成人中的发作性睡病与嗜睡症

Narcolepsy and hypersomnia in Norwegian children and young adults following the influenza A(H1N1) 2009 pandemic.
PubMed 文献 · Vaccine · 2017-03-13

研究通过链接挪威国家健康登记数据,随访2008年1月至2012年12月30岁以下人群,评估2009/2010年甲型H1N1流感感染或Pandemrix疫苗接种与发作性睡病或嗜睡症的关系。发作性睡病诊断经医院记录验证,采用Cox回归模型估计调整风险比。结果显示,接种疫苗后发作性睡病风险显著增加,调整HR为17.21(95%CI 6.28-47.14);感染后发作性睡病和嗜睡症风险也略有增加,但感染作用需谨慎解读,因流感报告不足。

要点

  • 接种Pandemrix疫苗后6个月内发作性睡病风险显著增加,调整HR为17.21(95%CI 6.28-47.14)。
  • 流感感染后6个月内发作性睡病风险增加,调整HR为3.31(95%CI 1.01-10.79)。
  • 流感感染后6个月内嗜睡症风险增加,调整HR为3.13(95%CI 1.12-8.76)。

核心结论

  • 研究证实大流行疫苗接种后发作性睡病风险增加,调整HR为17.21(95%CI 6.28-47.14)。
  • 流感感染后发作性睡病和嗜睡症风险也略有增加,但感染作用需谨慎解读,因流感报告不足。

研究设计与样本

  • 研究随访2008年1月至2012年12月挪威30岁以下人群,通过链接国家健康登记数据。
  • 发作性睡病诊断经医院记录验证,采用Cox回归模型估计调整风险比,以流感感染和疫苗接种为时间依赖暴露。

主要发现

  • 2009年挪威30岁以下人群共1,638,526人,其中3.6%被医生诊断为流感,41.9%接种了大流行流感疫苗。
  • 2009年10月1日至2012年12月31日期间,72人发作性睡病发病,305人被诊断为嗜睡症。
  • 感染后6个月内发作性睡病调整HR为3.31(95%CI 1.01-10.79),嗜睡症调整HR为3.13(95%CI 1.12-8.76)。
  • 接种疫苗后6个月内发作性睡病调整HR为17.21(95%CI 6.28-47.14),嗜睡症调整HR为1.54(95%CI 0.81-2.93)。

关键数值与推荐

  • 发作性睡病风险与疫苗接种的调整HR为17.21(95%CI 6.28-47.14)。
  • 发作性睡病风险与流感感染的调整HR为3.31(95%CI 1.01-10.79)。
  • 嗜睡症风险与流感感染的调整HR为3.13(95%CI 1.12-8.76)。
  • 嗜睡症风险与疫苗接种的调整HR为1.54(95%CI 0.81-2.93)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 感染的作用应谨慎看待,因流感存在报告不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Associations between influenza infection and sleep disorders are poorly studied. We investigated if pandemic influenza infection or vaccination with Pandemrix in 2009/2010 was associated with narcolepsy or hypersomnia in children and young adults. METHODS: We followed the Norwegian population under age 30 from January 2008 through December 2012 by linking national health registry data. Narcolepsy diagnoses were validated using hospital records. Risks of narcolepsy or hypersomnia were estimated as adjusted hazard ratios (HRs) in Cox regression models with influenza infection and vaccination as time-dependent exposures. RESULTS: Among the 1,638,526 persons under age 30 in Norway in 2009, 3.6% received a physician diagnosis of influenza during the pandemic, while 41.9% were vaccinated against pandemic influenza. Between October 1st 2009 and December 31st 2012, 72 persons had onset of narcolepsy and 305 were diagnosed with hypersomnia. The risk of a sleep disorder was associated with infection during the first six months, adjusted HR 3.31 with 95% confidence interval [CI], 1.01-10.79 for narcolepsy and adjusted HR 3.13 (95% CI, 1.12-8.76) for hypersomnia. The risk of narcolepsy was strongly associated with vaccination during the first six months adjusted HR 17.21 (95% CI, 6.28-47.14), while the adjusted HR for hypersomnia was 1.54 (95% CI, 0.81-2.93). CONCLUSIONS: The study confirms an increased HR of narcolepsy following pandemic vaccination. Slightly increased HRs of narcolepsy and hypersomnia are also seen after influenza infection. However, the role of infection should be viewed with caution due to underreporting of influenza.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Trogstad L, Bakken IJ, Gunnes N, et al. Narcolepsy and hypersomnia in Norwegian children and young adults following the influenza A(H1N1) 2009 pandemic. Vaccine. 2017. PMID: 28302408. doi:10.1016/j.vaccine.2017.02.053

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。